Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Thomas F. Patterson, George R. Thompson, David W. Denning et al. · Clinical Infectious Diseases · 2016 · 2.8K citations · Full text

Veterinary Medicine, Infectious Diseases, Internal Medicine +17

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Medicine, Molecular Medicine, Pharmacotherapy +16

Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

Oliver A. Cornely, Johan Maertens, Drew J. Winston et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 784 citations

Medicine, Pharmacokinetics, Pharmacology +17

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Ellen Weisberg, Christina Boulton, Louise Kelly et al. · Cancer Cell · 2002 · 602 citations · Full text

Medicine, Oncology, Pharmacology +14